UroAlert - GU Oncology Weekly

December 10, 2025

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Recurrence Patterns in a Large Contemporary Cohort of Patients With Non-Muscle Invasive Bladder Cancer.

Clinical Experience with URO17® in the Diagnosis and Surveillance of Bladder Cancer.

Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions.

A Clinically Practical Nomogram for Predicting Survival in Elderly Patients (≥ 65 Years) With Bladder Urothelial Carcinoma: A Study Based on SEER Database and External Validation.

Bladder Preservation after Neoadjuvant Therapy for Muscle-invasive Bladder Cancer in the Current Era: Myth and Reality - Beyond the Abstract

Diagnostic accuracy of the Vesical Imaging Reporting and Data System for muscle-invasive bladder cancer and its role in reducing repeat transurethral resection of bladder tumor: A systematic review.

The Future of Bladder Cancer Therapies: Integrating Hydrogel Scaffolds for Epigenetic Regulator Delivery.

The Impact of Avoiding Recurrence: New BRAVO Study Abstract at SUO 2025 Demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy Comparison

Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer?

Integration of gut microbiome and lipid metabolism reveals the anti-cancer effects of pentadecanoic acid on bladder cancer.

Virus-induced APOBEC3 transmutagenesis in bladder cancer initiation.

Enhancing RECK Expression Through miR-21 Inhibition: A Promising Strategy for Bladder Carcinoma Control.

Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with MIBC: primary analysis and biomarker results of SunRISe-4.

The Effect of Pelvic Lymph Node Dissection on Cancer-Specific Mortality in Partial Cystectomy According to Eligibility Criteria.

Modulating the PPARγ Pathway Upregulates NECTIN4 and Enhances Chimeric Antigen Receptor (CAR) T Cell Therapy in Bladder Cancer - Beyond the Abstract

Penile & Urethral Cancers

Penile Cancer Survivorship: Research Gaps in Psychosocial Health and Sexual Quality of Life.

Demographics, Clinical Characteristics, and a Stage-Based Analysis of Treatments and Outcomes for Squamous Cell Carcinoma of the Penis.

Renal Cancer

Immuno-oncologic profiling of renal masses using multiparametric MRI: a pilot study.

Tumor and Perirenal Adipose Tissue Radiomic Models for Pathological T-Stage Prediction and Biological Exploration in Clear Cell Renal Cell Carcinoma.

Oncological Results After Accidental Tumor Incision During Partial Nephrectomy.

Radiologic, Pathologic, and Deep Learning Predictors of Response to Immune Checkpoint Blockade in Renal Cell Carcinoma Patients Undergoing Post-Treatment Nephrectomy.

Ipilimumab and Nivolumab in Renal Cell Carcinoma: Real-World Experience in Rare Variant Renal Cell Carcinoma, Brain Metastases and Impact of Immune-Related Adverse Events and Steroid Use.

Ablative Techniques in Renal Tumours for Inoperable Patients: Step Forward in SBRT - Beyond the Abstract

From visualization to education: the role of 3D-Printed and virtual kidney models in training for renal cancer surgery, a systematic review.

Outcomes After Initial Noninterventional Management of Clinical Stage cT1b Renal Masses.

Mapping heterogeneity in the tumor microenvironment of renal cell carcinoma through single-cell omics.

BCL-xL Dependency in Chromophobe Renal Cell Carcinoma - Beyond the Abstract

Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma-An Observational Prospective Multicentre Diagnostic Test Cohort Study - Beyond the Abstract

Prostate Cancer

Evaluation of AI for prostate cancer detection in biparametric-MRI screening population data.

Artera Debuts ArteraAI Prostate Test (Post‑RP), Expanding its Oncology Portfolio

Incidence of ideal candidates for focal therapy: A scoping study following the FALCON Consensus Statements.

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary Endpoints.

Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer.

PARP Inhibitors in Prostate Cancer: Broad Use or Patient Selection?

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

Deciphering Resistance: Beyond the Androgen Paradigm; Report From the 2025 Coffey-Holden Prostate Cancer Academy Meeting.

Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations.

Neoadjuvant Systemic Therapy in High-risk Localised Prostate Cancer: Current Evidence and Future Directions.

Genetic Testing Among Black and White Patients With Advanced Prostate Cancer: A Retrospective Analysis of Testing Utilization and Referral Patterns.

Androgen deprivation therapy with apalutamide in the treatment of metastatic castration-sensitive prostate cancer: the systematic review of its effectiveness and applicability for Asian men in the targeted investigational treatment analysis of novel anti-

Prostate Cancer: Current Status of Novel Molecular Imaging and Future Prospects.

An investigation of race bias in deep learning-based segmentation of prostate MRI images.

Proteome-wide association study of prostate cancer risk across populations.

Prostate-specific Membrane Antigen Positron Emission Tomography Versus Conventional Imaging for Preoperative Staging High-risk Prostate Cancer Patients Undergoing Surgery for cN0M0 Disease: An European Association of Urology-Young Academic Urologists Pros

Defining Long-Term Prostate Cancer Treatment Patterns and Adverse Urologic Events: A Methodological Framework and Patient Outcomes Using the Utah Population Database.

The Role of Comorbidities in Treatment Decision-Making across the Spectrum of Prostate Cancer: A Podcast.

National patterns of brachytherapy boost use for intermediate- and high-risk prostate cancer: Bridging the gap between evidence and practice.

FDA Approves IsoPSA® -- Cleveland Diagnostics’ Novel Blood-Based Prostate Cancer Test

Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer.

Improving Prostate MRI: Lessons Learned from the American College of Radiology's Prostate MR Image Quality Improvement Collaborative.

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.

A Randomised Clinical Trial Comparing Two Biopsy Templates and Follow-up Schedules for Men on Active Surveillance for Low-risk Prostate Cancer: SAMS.

European Registry of Next Generation Imaging in Advanced Prostate Cancer (RING): protocol for an international, prospective registry study.

Using Patient-Reported Outcomes from the PROCLAIM Trial to Assess the Impact of Universal Germline Genetic Testing for Prostate Cancer Patients - Beyond the Abstract

First-Line [177Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer - Beyond the Abstract

Upper Tract Tumors

In medio stat virtus: Exploring the potential of the pulsed thulium:YAG laser in the endoscopic management of upper tract urothelial carcinoma.

Low incidence of venous thromboembolic complications following single-port robotic surgeries for upper and lower tract urological malignancies: a report from the Single-Port Advanced Research Consortium (SPARC).

Outcomes of sequential therapy for advanced upper tract urothelial cancer and bladder cancer.

Testicular Cancer

Can novel biomarkers augment traditional surveillance paradigms in early-stage testicular germ cell tumors? A case study in pre-clinical relapse detection using a combination micro-RNA-371a-3p and 372-3p assay.

Screening of adolescents for testicular cancer-a nationwide retrospective cohort study.

Low level of plasma DNase is associated with worse clinical outcome in testicular germ cell tumor patients and exogeneous DNase I improves (Leverages) cisplatin treatment efficacy.

GAMMA: Results from a Phase II Study for Relapsed Germ Cell Tumors using an Oxaliplatin-Based Treatment Regimen.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC